Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Antonio Giannelli

Physician Assistant Lansing, MI Physician Assistant

NPI 1841369642 CMS profile 10463620

4052 Legacy Pkwy, Suite 200, Lansing, MI 48911

Open in the dashboard

General payments

$21,645

1,121 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Antonio Giannelli of Lansing, MI is reported in the CMS Open Payments database as having received $21,645 across 1,121 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,101 25
2024 General $5,152 237
2023 General $5,032 277
2022 General $5,531 296
2021 General $4,829 286

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Antonio Giannelli
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Antonio Giannelli were reported at $1,101. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Antonio Giannelli Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $4,829 $132 $37–$438 $132
2022 $5,531 $155 $48–$522 $149
2023 $5,032 $167 $52–$557 $160
2024 $5,152 $178 $55–$600 $164
2025 $1,101 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $4,574 366 payments
  2. Amgen Inc. $3,852 171 payments
  3. AbbVie, Inc. $2,733 141 payments
  4. UCB, Inc. $2,424 85 payments
  5. AstraZeneca Pharmaceuticals LP $1,285 53 payments
  6. Novartis Pharmaceuticals Corporation $1,037 41 payments
  7. Mallinckrodt Hospital Products Inc. $845 36 payments
  8. Lilly USA, LLC $543 26 payments
  9. Pfizer Inc. $461 31 payments
  10. ANI Pharmaceuticals, Inc. $421 21 payments
  11. Other $3,471 150 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $21,107 1,112 payments
  2. Education $538 9 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $3,853 300 payments
  2. RINVOQ $2,046 117 payments
  3. Cimzia $1,832 75 payments
  4. SIMPONI ARIA $1,818 165 payments
  5. Enbrel $1,058 51 payments
  6. SAPHNELO $1,053 49 payments
  7. Otezla $957 36 payments
  8. ACTHAR $845 36 payments
  9. EVENITY $710 35 payments
  10. STELARA $664 58 payments
  11. Other $11,224 603 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

3,566

Median for Physician Assistant: 241

Drug cost

$2,763,602

Median for Physician Assistant: $4,110

Branded share of claims

27.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 115 $853,100
Rinvoq Upadacitinib Brand 45 $282,316
Orencia Abatacept Brand 51 $278,782
Otezla Apremilast Brand 47 $219,604
Enbrel Mini Etanercept Brand 22 $188,312
Xeljanz Xr Tofacitinib Citrate Brand 22 $146,352
Enbrel Sureclick Etanercept Brand 18 $139,675
Enbrel Etanercept Brand 19 $137,213
Cosentyx Sensoready (2 Pens) Secukinumab Brand 15 $107,453
Orencia Clickject Abatacept Brand 14 $100,507

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$651 45 —
SAPHNELO
$427 — —
TREMFYA
$419 — —
SIMPONI ARIA
$309 — —
ACTHAR
$295 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

1,121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record